Payment overview · 2025
General Payments
$4,202.64
36 reported records · 11 companies
Healthcare provider profile · identity verified
Grissel Rios, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN JUAN, PR · NPI 1821072935
Verified facts
What the public records show
CMS Open Payments records show Grissel Rios, M.D. received $4,202.64 in general payments during 2025 across 36 reported records.
ARGENX US, INC. accounted for 40.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Orencia, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Orencia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Simponi by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $1,704.60 | 40.6% | 9 | 2025 |
| UCB SA | Unresolved — no canonical attribution shown | $1,693.48 | 40.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $276.16 | 6.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $113.45 | 2.7% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $100.14 | 2.4% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $89.99 | 2.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $61.37 | 1.5% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $50.00 | 1.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.00 | 1.2% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $33.90 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.55 | 0.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $2,646.04 | 7 |
| Food and Beverage | $1,415.21 | 26 |
| Education | $141.39 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $1,704.60 | 9 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $276.16 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $161.51 | 4 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $89.99 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $89.99 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $51.40 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $50.00 | 2 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $49.00 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $33.90 | 1 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
169 | 35 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 877 | 138 |
| Gabapentin | Gabapentin | 860 | 176 |
| Methotrexate | Methotrexate Sodium | 536 | 78 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 396 | 81 |
| Celecoxib | Celecoxib | 236 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 220 | 52 |
| Famotidine | Famotidine | 180 | 40 |
| Baclofen | Baclofen | 177 | 56 |
| Synthroid | Levothyroxine Sodium | 169 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 156 | 46 |
| Meloxicam | Meloxicam | 140 | 43 |
| Humira(Cf) Pen | Adalimumab | 138 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 114 | 32 |
| Alendronate Sodium | Alendronate Sodium | 112 | 31 |
| Nabumetone | Nabumetone | 110 | 33 |
| Diclofenac Potassium | Diclofenac Potassium | 105 | 29 |
| Pregabalin | Pregabalin | 102 | 26 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 96 | 19 |
| Tramadol Hcl | Tramadol Hcl | 96 | 41 |
| Risedronate Sodium | Risedronate Sodium | 92 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 91 | 16 |
| Xeljanz Xr | Tofacitinib Citrate | 91 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 79 | 28 |
| Sulindac | Sulindac | 78 | 20 |
| Omeprazole | Omeprazole | 75 | 16 |
| Actemra Actpen | Tocilizumab | 74 | suppressed |
| Lidocaine | Lidocaine | 72 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 66 | 16 |
| Losartan Potassium | Losartan Potassium | 63 | 17 |
| Enbrel Sureclick | Etanercept | 62 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 14 |
| Naproxen | Naproxen | 58 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 11 |
| Montelukast Sodium | Montelukast Sodium | 54 | 12 |
| Prolia | Denosumab | 53 | 38 |
| Orencia Clickject | Abatacept | 51 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 46 | suppressed |
| Rinvoq | Upadacitinib | 44 | suppressed |
| Colchicine | Colchicine | 41 | 16 |
| Humira(Cf) | Adalimumab | 40 | suppressed |
| Allopurinol | Allopurinol | 39 | suppressed |
| Benlysta | Belimumab | 38 | suppressed |
| Azathioprine | Azathioprine | 37 | suppressed |
| Folic Acid | Folic Acid | 35 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 33 | suppressed |
| Simvastatin | Simvastatin | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 28 | suppressed |
| Orencia | Abatacept | 27 | suppressed |
| Savella | Milnacipran Hcl | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Desonide | Desonide | 23 | 11 |
| Tacrolimus | Tacrolimus | 23 | suppressed |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 21 | suppressed |
| Simponi | Golimumab | 21 | suppressed |
| Lisinopril | Lisinopril | 20 | suppressed |
| Actemra | Tocilizumab | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 16 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 16 | suppressed |
| Ofev | Nintedanib Esylate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Piroxicam | Piroxicam | 15 | suppressed |
| Carvedilol | Carvedilol | 14 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Kevzara | Sarilumab | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olumiant | Baricitinib | 12 | suppressed |
| Teriparatide | Teriparatide | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Mupirocin | Mupirocin Calcium | 11 | suppressed |
| Taltz Autoinjector | Ixekizumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,202.64 · 36 records | ARGENX US, INC. | ACTHAR, BENLYSTA, Bimzelx, OPSUMIT, ORENCIA, RINVOQ, Sotyktu, TREMFYA, UPTRAVI, VYVGART HYTRULO, WINREVAIR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error